Efficacy of the current therapeutic option in the NUP98-HBO1–derived CMML model. (A) Schematic of in vitro and in vivo treatment. (B) Cell proliferation in the liquid culture of the NUP98-HBO1–transduced murine BM cells. 5-Aza was added every other day to maintain the indicated concentration. Data are presented as mean ± SD from triplicates. (C-D) WBC counts, Hb, and Plts counts in PB (C) and PB chimerism (D) of the NUP98-HBO1 BMT mice with or without 5-Aza treatment (Vehicle, n = 5; 5-Aza, n = 6). Data are presented as mean ± SD. (E) Percentage of monocytes (CD11b⁺ CD115⁺) in PB from the NUP98-HBO1 BMT mice with or without 5-Aza treatment (Vehicle, n = 5; 5-Aza, n = 6). Data are presented as mean ± SD. (F) Survival of NUP98-HBO1 BMT mice with or without 5-Aza treatment (Vehicle, n = 5; 5-Aza, n = 6). *P < .05, **P < .01, ***P < .001, ****P < .0001. ip, intraperitoneally.